Characterization of the substituted N-triazole oxindole, TROX-1, a small molecule, state-dependent inhibitor of Ca_{2} calcium channels


Running title: Characterization of TROX-1, a state-dependent Ca\textsubscript{v}2 inhibitor

Corresponding author:
Owen B. McManus
Johns Hopkins Ion Channel Center
Department of Neuroscience
Johns Hopkins School of Medicine
733 North Broadway
Baltimore, MD 21205
443-287-4410
410-614-1001 (FAX)
owen_mcmanus@jhmi.edu

Number of text pages: 25
Number of tables: 1
Number of figures: 7
Number of references: 40
Number of words in Abstract: 250
Number of words in Introduction: 592
Number of words in Discussion: 1466

Non-standard Abbreviations: bMHN-4, CBK, and 2H8, Ca\textsubscript{v}2.2 HEK cell lines; Ca\textsubscript{o}, voltage-gated calcium channel; DMSO, dimethyl sulfoxide; GVIA, \textomega\textsuperscript{-}conotoxin GVIA; TROX-1, (3\textsuperscript{R})-5-(3-chloro-4-fluorophenyl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1-(1\textsubscript{H}-1,2,4-triazol-3-yl)-1,3-dihydro-2\textsubscript{H}-indol-2-one.
Abstract
Biological, genetic, and clinical evidence provide validation for N-type calcium channels (CaV2.2) as therapeutic targets for chronic pain. A state-dependent CaV2.2 inhibitor may provide an improved therapeutic window over ziconotide, the peptidyl CaV2.2 inhibitor used clinically. Supporting this notion, we recently reported that the state-dependent CaV2 inhibitor TROX-1 has an improved therapeutic window compared to ziconotide in preclinical models. Here we characterize TROX-1 inhibition of Cav2.2 channels in more detail. When channels are biased towards open/inactivated states by depolarizing the membrane potential under voltage-clamp electrophysiology, TROX-1 inhibits CaV2.2 channels with an IC50 of 0.11 μM. The voltage-dependence of CaV2.2 inhibition was examined using automated electrophysiology. TROX-1 IC50 values were 4.2 μM at -110 mV, 0.90 μM at -90 mV, and 0.36 μM at -70 mV. TROX-1 displayed use-dependent inhibition of CaV2.2 with a 10-fold IC50 separation between first (27 μM) and last (2.7 μM) pulses in a train. In a fluorescence-based calcium influx assay, TROX-1 inhibited CaV2.2 channels with an IC50 of 9.5 μM under hyperpolarized conditions and 0.69 μM under depolarized conditions. Lastly, TROX-1 potency was examined across the CaV2 subfamily. Depolarized IC50 values were 0.29 μM, 0.19 μM and 0.28 μM by manual electrophysiology using matched conditions and 1.8 μM, 0.69 μM and 1.1 μM by calcium influx for CaV2.1, CaV2.2 and CaV2.3, respectively. Together, these in-vitro data support the idea that a state-dependent, non-subtype selective CaV2 channel inhibitor can achieve an improved therapeutic window over the relatively state-independent, CaV2.2-selective inhibitor ziconotide in preclinical models of chronic pain.
Introduction

The Ca\textsubscript{V}2 subfamily of voltage-dependent calcium channels serves a critical role in the nervous system. This subfamily consists of Ca\textsubscript{V}2.1 (P/Q-type), Ca\textsubscript{V}2.2 (N-type) and Ca\textsubscript{V}2.3 (R-type) channels. These calcium channels provide the main pathway for voltage-triggered calcium influx and subsequent neurotransmitter release at many synapses. Although all three subfamily members likely contribute to processing nociceptive inputs (Pietrobon, 2005), most drug discovery efforts seeking treatments for pathological pain have focused on the Ca\textsubscript{V}2.2 subtype (Yamamoto and Takahara, 2009).

There is extensive evidence to support Ca\textsubscript{V}2.2 as a target for chronic pain treatment. Ca\textsubscript{V}2.2 channels are highly expressed in laminae I and II of the spinal cord (Gohil et al., 1994; Westenbroek et al., 1998) and are up-regulated in behavioral pain models (Abbadie et al., 2010; Cizkova et al., 2002). Laminae I and II serve as critical relay points in the transmission of pain information into the CNS, where primary nociceptors make synaptic connections with dorsal horn neurons of the spinal cord. Opening of presynaptic Ca\textsubscript{V}2.2 channels in response to depolarization of the primary afferent terminal triggers release of transmitter into the synaptic cleft (Evans et al., 1996). Blocking these Ca\textsubscript{V}2.2 channels with conopeptides attenuates nociception in behavioral models of neuropathic and inflammatory pain (Malmberg and Yaksh, 1995; Scott et al., 2002). Furthermore, Ca\textsubscript{V}2.2 knockout mice display reduced pain sensitivity in a number of pain models (Abbadie et al., 2010; Hatakeyama et al., 2001; Kim et al., 2001; Saegusa et al., 2001). Perhaps most convincing are the clinical data from ziconotide, a selective peptide blocker of Ca\textsubscript{V}2.2 channels, which is efficacious in the treatment of chronic pain (Miljanich, 2004).
While ziconotide provides efficacy against chronic pain its use is limited by its small therapeutic window and intrathecal route of administration (Miljanich, 2004; Staats et al., 2004). Although some state-dependence to ziconotide block is revealed at very negative potentials, within physiological voltage ranges ziconotide potently inhibits CaV2.2 channels regardless of whether they are in the open, closed, or inactivated state (Feng et al., 2003; Stocker et al., 1997). Small molecule inhibitors demonstrating strong state-dependent inhibition have been well described for L-type and T-type calcium channels (e.g. (Bean, 1984; McDonough and Bean, 1998) and it has been proposed that a state-dependent CaV2.2 inhibitor, which preferentially binds to channels in open or inactivated states, may provide efficacy with an improved therapeutic window over ziconotide due to enhanced activation of CaV2.2 channels in pain conditions (McGivern and McDonough, 2004; Snutch, 2005; Winquist et al., 2005). A number of small molecule CaV2.2 inhibitors have been described in the literature (reviewed in Yamamoto and Takahara, 2009), although detailed mechanistic characterizations of these compounds have not been reported, preventing determination of the value of state-dependent inhibitors in pain treatment.

TROX-1, a substituted N-triazole oxindole, is a CaV2.2 inhibitor which exhibits efficacy in a number of animal pain models with a therapeutic window for both cardiovascular and CNS side effects (Abbadie et al., 2010). Here we show electrophysiologically that TROX-1 inhibits CaV2.2 channels in both a state-dependent and use-dependent manner. Since state-dependent calcium channel inhibitors can exhibit apparent subtype selectivity due to different levels of channel inactivation across channel subtypes, we measured the activity of TROX-1 on members of the CaV2 subfamily at
various levels of inactivation. When the differences in inactivation are accounted for, TROX-1 is shown to have little molecular subtype selectivity within the Ca\textsubscript{\textit{v}2} subfamily. Nevertheless, these results suggest that ‘functional’ selectivity may still be obtained over Ca\textsubscript{\textit{v}2} channel isoforms which have more depolarized inactivation-voltage relationships or Ca\textsubscript{\textit{v}2} channels that are expressed in cells with more hyperpolarized resting potentials.
Materials and Methods

Chemicals

TROX-1 ((3R)-5-(3-chloro-4-fluorophenyl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1-(1H-1,2,4-triazol-3-yl)-1,3-dihydro-2H-indol-2-one) was synthesized at Merck Research Labs, Rahway, NJ. Stock solutions of TROX-1 were prepared in DMSO at 10 mM and diluted into assay buffer solutions immediately prior to use. ω-Conotoxin GVIA was obtained from Sigma-Aldrich (St. Louis, MO).

Cell lines and growth conditions

Stable HEK293 cell lines expressing human CaV2 calcium channels were previously described (Dai et al., 2008). The CaV2.1 stable line expressed the α1A-2 (P-type) splice variant (Hans et al., 1999). The CaV2.2 cell lines (2H8 and CBK) utilized the long form of α1B-1 (Williams et al., 1992). For CaV2.3, the α1E-3 splice variant was used (Williams et al., 1994). Each cell line expressed α2βδ-1 and β3a auxiliary subunits (Williams et al., 1992). Following creation of the stable cell lines expressing calcium channels, each line was transfected with cDNA encoding human Kir2.3 (KCNJ4) (Perier et al., 1994) and clonal selection was performed. For electrophysiological experiments, an additional CaV2.2 cell line (bMHN-4) was produced that afforded increased expression levels and improved performance in electrophysiological assays. HEK-293 cells were transfected using a dual vector approach, pcDNA3.1 with long form α1B-1 and pBudCE4 with α2δ-1 and β3. Clones were selected based on CaV2.2 channel expression using 125I-ω-CgTx-GVIA binding levels and high-expressing clones were further characterized in electrophysiological experiments. Cell lines were cultured at 37 °C in DMEM (Cellgro #10-013-CM) supplemented with 10% fetal bovine serum.
(Invitrogen/Gibco #16000-036), penicillin, streptomycin, and glutamine additive (Invitrogen/Gibco #10378-016) and appropriate selection antibiotics. CaV2.1 and CaV2.3 cell lines were maintained at 5% CO2; CaV2.2 cells were maintained at 10% CO2. CaV2.2 and CaV2.3 cell lines were maintained at 30 °C for one day and CaV2.1 cells for two to three days prior to use to enhance expression levels.

**Manual Electrophysiology**

Membrane currents were recorded from the stable HEK293 recombinant cell lines expressing either CaV2.1, CaV2.2 (bMHN-4 cell line), or CaV2.3 channels using the whole-cell patch clamp technique with a HEKA (Port Washington, NY) EPC 10 patch-clamp or an Axopatch 200B patch-clamp amplifier. Fire-polished borosilicate glass electrodes had resistances from 1-3 MΩ when filled with internal solution. Solutions were applied to cells by bath perfusion via gravity and flow of solution through the chamber was maintained at all times. Cells exhibiting stable current amplitudes were challenged with compound dissolved in DMSO such that the final DMSO concentration typically did not exceed 0.1% of the external solution and did not affect assay results. For experiments testing the effects of 30 μM TROX-1, control and compound solutions had a final DMSO concentration of 0.3%. Compounds were added in escalating concentrations for a minimum of 4 minutes and percent inhibition was measured after steady state inhibition was achieved at each concentration. IC50 values for CaV inhibition were calculated from the fits to the Hill equation (Percent Inhibition = 100*(1/(1+(IC50/[Compound])^nH))) with the slope, nH, fixed to 1. For the initial manual electrophysiology experiments (Figures 1 and 2), bMHN-4 cells were grown on poly-D-
lysine coated coverglass. The extracellular solution contained (in mM): 5 BaCl₂, 139 CsCl, 1 MgCl₂, 10 HEPES, 10 glucose, 10 sucrose, pH adjusted to 7.4 with CsOH. The intracellular solution contained (in mM): 126.5 Cs-methanesulfonate, 2 MgCl₂, 11 EGTA, 10 HEPES, 2 Na₂-ATP; osmolarity was adjusted to 295 mOsm using sucrose and pH to 7.3 using CsOH. Leak subtraction was performed using a P/4 protocol. The purpose in some manual electrophysiology experiments was to compare inhibition of Caᵥ2.2 channels with inhibition of Caᵥ2.1 and Caᵥ2.3 channels (Figure 5). Due to differences in growth patterns between the three cell lines, cells were acutely dissociated from T25 flasks before use. To compensate for lower channel expression levels in the Caᵥ2.1 and Caᵥ2.3 cell lines, a 20 mM barium external solution containing (in mM): 120 NaCl, 20 BaCl₂, 4.5 KCl, 0.5 MgCl₂, 10 HEPES, 10 glucose, pH 7.4 with NaOH, was utilized for all three cell lines in these experiments. The internal solution for these experiments contained (in mM): 130 CsCl, 10 EGTA, 10 HEPES, 2 MgCl₂, 3 MgATP, pH 7.3 with CsOH.

For generating the current versus voltage relationship for the bMHN-4 line, cells were voltage-clamped at -100 mV and peak currents measured during 15 ms voltage steps ranging from -65 mV to +50 mV in 5 mV increments. Following each step, cells were stepped back down to -50 mV where deactivation was slow enough to measure tail currents. Normalized tail current measurements were used for generating the activation curve. For the inactivation protocol, cells were voltage-clamped at -110 mV and stepped to voltages ranging from -130 to -10 mV for 10 seconds (prepulses), and then to +10 mV to elicit current through non-inactivated channels. Sweeps were repeated every 40 seconds. Control currents were elicited before each prepulse to assure that there was not
substantial rundown and that the currents were sufficiently recovered from the previous prepulse. Resulting data were fit to a Boltzmann function: 

\[ y = \frac{1}{1 + \exp\left(\frac{V_h - V}{k}\right)} \]

where \( y \) is the current normalized with respect to the maximal current, \( V_h \) is the voltage at which half activation or inactivation is reached, \( V \) is the voltage, and \( k \) is the slope factor. Data are reported as the mean ± S.E.M.

**Automated Electrophysiology using PatchXpress**

PatchXpress™ is a 16-well whole-cell automated patch clamp device that operates asynchronously with fully integrated fluidics (Molecular Devices Corp, Sunnyvale, CA). For PatchXpress™ experiments, cells were grown in T75 culture flasks and dissociated with trypsin 30-60 minutes before use. Capacitance and series resistance compensation were automatically applied and no correction for liquid junction potentials was employed. Leak subtraction was performed using the P/N procedure. Voltage protocols and the recording of membrane currents were performed using the PatchXpress™ software/hardware system and current amplitudes were calculated with DataXpress™ software. In order to increase current amplitudes and assay reliability, the same 20 mM barium external solution and corresponding internal solution used for the manual electrophysiology experiments were also used for the PatchXpress™ experiments. The bMHN-4 cell line was used for the state-dependent assay and the CBK cell line was used for the use-dependent assay. Compounds were added in escalating concentrations (0.3 μM to 30 μM) using an integrated pipettor from a 96-well compound plate. Percent inhibition of peak current by TROX-1 was calculated from the ratio of the current amplitude in the presence and absence of compound. Data are reported as the mean ±
S.E.M. IC$_{50}$ values for Cav2.2 inhibition were calculated from fits of the Hill equation with the slope fixed to 1.

**Cav2.x Channel Calcium Influx Assays**

Fluorescence-based calcium influx assays as described in Dai et al. (2008) were used to characterize the effects of TROX-1 on Cav2.x channels. Expression of Kir2.3 channels in each cell line allowed control of cell membrane potential through changes in bath potassium concentration (Dai et al., 2008). TROX-1 was incubated with each cell line in the presence of varying levels of bath potassium concentration to assess channel inhibition at different membrane potentials and levels of channel inactivation. After 30 minutes compound incubation, channel opening was initiated by 1:1 addition of buffer solution containing 140 mM potassium. Calcium influx signals were measured using a 384 well FLIPR Tetra™ (Molecular Devices Corp, Sunnyvale, CA) and calcium indicator dye (Fluo-4). The assay protocol is described below. Cells were seeded in poly-D-lysine coated 384-well plates and kept in an incubator overnight at 30 °C for Cav2.2 and Cav2.3 cell lines and at 30 °C for two to three days for Cav2.1 cells. Media was removed and cells were washed with 50 µl Dulbecco’s Phosphate Buffered Saline (D-PBS) with calcium & magnesium (Invitrogen; 14040). Fifty µl of 4 µM Fluo-4 (Molecular Probes; F-14202) and 0.02% pluronic acid (Molecular Probes; P-3000) prepared in D-PBS supplemented with 10 mM glucose & 10 mM HEPES/NaOH; pH 7.4 was added to each well. Cells were incubated in the dark at 25 °C for 60-70 min. Dye was removed and cells were washed with 60 µl of Potassium Pre-polarization Buffer. (PPB (in mM): x KCl, 150-x NaCl, 0.8 CaCl$_2$, 1.7 MgCl$_2$, 10 HEPES, pH=7.2). Thirty µl of PPB was added to each well with or without test compound and cells were
incubated in the dark at 25 °C for 30 min. Fluorescence intensity was measured on a FLIPR Tetra™ instrument (excitation = 480 nm, emission = 535 nm). While continuously reading fluorescence intensity for 40 s, 30 µl of Depolarization Buffer (in mM): 140 KCl, 10 NaCl, 0.8 CaCl₂, 1.7 MgCl₂, 10 HEPES, pH=7.2, which is 2x the final assay concentration, was added to each well after 10 s. Peak fluorescent signal intensity was determined and the amplitude of the peak signal, normalized to baseline, was used to measure channel inhibition by test compounds. Data are reported as the mean ± S.E.M. IC₅₀ values for Cav2.x inhibition were calculated from fits of the Hill equation to the titration data.
Results

Characterization of CaV2.2 cell lines

The CaV2.2 (2H8) cell line used in the calcium influx assay and the CaV2.1 and CaV2.3 cell lines used in both the electrophysiological and influx assays were previously characterized (Dai et al., 2008). For electrophysiological studies involving CaV2.2, a new cell line was created with improved current stability. New cell lines were created using a dual vector approach (see Materials and Methods). Clones with high CaV2.2 expression were initially selected using an 125I-ω-CgTx-GVIA binding assay and then characterized electrophysiologically on the PatchXpress™, an automated patch clamp platform, to select clones with high functional expression, appropriate biophysical properties, and favorable current stability over time. Using these criteria, the bMHN-4 clone was selected for electrophysiological experiments. The current expressed in the bMHN-4 cell line was larger than that in the original CBK line and, although smaller than that expressed in the 2H8 cell line, was more stable over time (Table 1, Fig. 1A). The bMHN-4 cell line was characterized in more detail by conventional electrophysiology. Maximal current was elicited at ~ +5 mV with half activation occurring at +4 mV and half inactivation at -80 mV (Fig. 1B). Addition of 500 nM of the CaV2.2-selective peptide inhibitor, ω-conotoxin-GVIA, inhibited 99% of the current elicited from voltage steps to +10 mV (n=3 cells; Fig. 1C).

TROX-1 inhibits CaV2.2 currents in a voltage- and use-dependent manner

State-dependent inhibition of CaV2.2 channels by TROX-1 was evaluated by applying the compound at two different membrane potentials using the bMHN-4 recombinant cell line.
Closed state inhibition was estimated during TROX-1 application at a hyperpolarized membrane potential (-115 mV), where channels are biased towards the closed-state; the level of channel inhibition was determined during 20 ms voltage steps to +10 mV every 30 seconds to elicit current through available, unblocked channels. Potential inhibition of inactivated and/or open channels was explored by applying TROX-1 at more depolarized membrane potentials with approximately 30% apparent channel inactivation (-75 mV to -85 mV). Peak currents were measured during 50 ms voltage steps to +10 mV every 15 seconds. For both hyperpolarized and depolarized voltage formats, after stable baseline currents were obtained, compounds were applied by bath perfusion until steady-state inhibition was achieved. Representative current traces for CaV2.2, +/- 300 nM TROX-1, are shown for the depolarized (Fig. 2B) and the hyperpolarized (Fig. 2C) assay formats. Using the depolarized protocol, TROX-1 inhibited CaV2.2 in a concentration-dependent manner with an estimated IC50 of 0.11 μM (Fig. 2D). Under hyperpolarized conditions, where channels are biased towards the closed state, TROX-1 was less potent, blocking only 14 ± 6% and 45 ± 7% of the calcium current at 0.3 μM and 3 μM, respectively.

The dependence of TROX-1 activity on membrane potential and channel state was further characterized using PatchXpress™. As for the manual patch clamp assay, cells were stepped to +10 mV every 15 seconds to elicit current and evaluate inhibition. The holding potential, however, was varied in 20 mV increments from -110 mV to –70 mV for different groups of cells. Representative current versus time plots and current traces are shown for TROX-1 inhibition of CaV2.2 from a holding potential of -70 mV (Fig. 3A) and -110 mV (Fig. 3B). Similar to the results for manual patch assay, the apparent
potency of TROX-1 depended on the holding membrane potential with the IC$_{50}$ shifting from 0.36 μM at -70 mV to 4.2 μM at -110 mV (Fig. 3C).

Use-dependent inhibition of Ca$_V$2.2 channels expressed in the CBK cell line was examined using PatchXpress™. The CBK cell line was chosen because the currents in response to voltage trains were more stable than the currents in 2H8 or bMHN-14 cells. The cause of these stability differences is unclear but may involve differences in channel inactivation across the cell lines. The Ca$_V$2.2 currents in CBK cells exhibit a more depolarized, two component steady-state inactivation curve probably due to limiting expression of β3a (discussed in Dai et al., 2008). CBK cells were voltage clamped at –60 mV, which corresponds to ~80% availability at steady-state, and trains of 20 pulses (25 ms) to +20 mV were applied at a frequency of 2 Hz every 5 minutes. Representative currents at pulse 1 and pulse 20 under control conditions and in the presence of 3 μM TROX-1 are shown in Fig. 4A. Inspection of the time course of current reduction during the pulse train shows that inhibition mainly develops over the first 10 pulses and has reached steady-state by the 20$^{th}$ pulse (Fig. 4C). The averaged data presented in Fig. 4B illustrates that TROX-1 inhibited the current elicited at pulse 20 more potently (IC$_{50}$ = 2.4 μM) than the current elicited at pulse 1 (IC$_{50}$ = 24 μM) indicating enhanced inhibition of Ca$_V$2.2 channels after a train of depolarizing pulses that open and inactivate Ca$_V$2.2 channels.

Together, these data demonstrate TROX-1 inhibits Ca$_V$2.2 channels in both a voltage- and use-dependent manner and are consistent with state-dependent inhibition of inactivated and/or open channels by TROX-1.
TROX-1 inhibits other members of the CaV2 subfamily of calcium channels

In manual electrophysiology experiments TROX-1 activity was compared across other members of the CaV2 subfamily of calcium channels to assess its selectivity profile. Lower expression levels in the CaV2.1 and CaV2.3 cell lines required an increase in the concentration of the barium charge carrier from 5 mM (Fig. 2) to 20 mM. TROX-1 activity on CaV2.2 was re-assessed using 20 mM barium as the charge carrier to allow for a direct comparison of potency across all three CaV2 subfamily members without concern for potency shifts that might result from differences in the concentration of the charge carrier. TROX-1 inhibition of CaV2 currents was measured using both ‘hyperpolarized’ and ‘depolarized’ voltage formats as described previously (Dai et al., 2008). In brief, for the hyperpolarized format, cells were voltage-clamped at -100 mV and stepped to +10 mV every 15 seconds. For the depolarized format, cells were also stepped to +10 mV every 15 seconds, however, cells were first voltage-clamped at -100 mV to establish a baseline current amplitude and then depolarized to a holding membrane potential which resulted in ~30% inactivation of the current. For CaV2.2 and CaV2.3 channels this voltage was typically -70 to -75 mV. For the less inactivating CaV2.1 cell line, this voltage was ~-40 mV. Under the hyperpolarized conditions, TROX-1 showed an apparent selectivity for CaV2.2 and CaV2.3 over CaV2.1 (Fig. 5, squares: IC50 = 37 μM for CaV2.1, 1.1 μM for CaV2.2, and 1.2 μM for CaV2.3). However, when TROX-1 inhibition of CaV2 channels was assessed under depolarized conditions where the channels exhibited similar levels of inactivation, no selectivity was apparent (Fig. 5, circles: IC50 = 0.29 μM for CaV2.1, 0.19 μM for CaV2.2, and 0.28 μM for CaV2.3).
TROX-1 inhibition of Cav2 channels was also examined in a calcium influx assay on a FLIPR™ with the throughput to assess inhibition of all three subfamily members across a range of conditions (see Dai et al., 2008). This assay utilizes Cav2.1, Cav2.2 and Cav2.3 cell lines which co-express the Kir2.3 inward rectifier potassium current and therefore allows the membrane potential of the cells to be varied by changing the external potassium concentration. Cells were pre-incubated in potassium pre-polarization buffers with variable potassium concentrations, +/- TROX-1, and then channel opening triggered with a high K⁺ depolarization buffer (see Methods). Figure 6 compares TROX-1 inhibition of calcium influx when the pre-incubation external potassium was relatively low (A, 4 mM), and when the external potassium was higher (B, 14 mM). The top section of each subpanel in Fig. 6 shows example calcium influx data from a row of twenty four wells in a 384 well assay plate. The leftmost two wells in each row contain a positive toxin control followed by two wells containing control buffer and the remaining wells containing increasing concentrations of TROX-1 in duplicate. Analysis of concentration-response data are shown in the bottom section of each subpanel. Using these potassium concentrations, Cav2.2 and Cav2.3 channels show a marked shift in TROX-1 potency between the 4 mM K⁺ and 14 mM K⁺ conditions (IC₅₀ values decreasing from 9.48 µM to 0.69 µM for Cav2.2 and 5.13 µM to 1.09 µM for Cav2.3), while the shift for Cav2.1 channels was more moderate (IC₅₀ decreased from 25.6 µM to 12.4 µM). A large part of this differential shift between the Cav2 subfamily members is a result of the weaker potency of TROX-1 on Cav2.1, relative to Cav2.2 and Cav2.3, under the 14 mM K⁺ condition. Although the three cell lines should be at similar voltages in 14 mM K⁺ (Dai et al., 2008), the fluorescence values from Fig. 6 show that the calcium...
influx for Cav2.2 and Cav2.3 is reduced in the 14 mM K⁺ condition but relatively unchanged for Cav2.1. This is consistent with the more depolarized inactivation-voltage relationship of Cav2.1 relative to Cav2.2 and Cav2.3 (see Fig. 1B and Dai et al., 2008, Fig. 2D).

To better understand the relationship between calcium channel inactivation and potency, TROX-1 inhibition of Cav2.1, Cav2.2 and Cav2.3-mediated calcium influx was examined across a range of external potassium concentrations. The dependency of the calcium signal on external potassium varied across the three Cav2 subfamily members with Cav2.1 being the most right shifted (Fig. 7A-C, black hollow squares). Similarly, the dependency of TROX-1 potency on external potassium varied across the three subfamily members with Cav2.1 again being the most right-shifted (Fig.7A-C, colored open symbols). Interestingly, if the IC₅₀ for TROX-1 inhibition is plotted versus the fractional reduction in calcium signal, there is little difference in the potency of TROX-1 across the three Cav2 subfamily members (Fig. 7D). These results suggest that the apparent differences in TROX-1 potencies observed under different assay conditions are simply a reflection of the degree of inactivation between the channels. Taken together, these data show that TROX-1 is a highly state-dependent inhibitor of all three members of the Cav2 subfamily of calcium channels with very little, if any, true molecular selectivity across subtypes.
Discussion

The results reported here show that the substituted N-triazole oxindole, TROX-1, is a potent state-dependent inhibitor of human Ca\textsubscript{V}2.2 calcium channels. Measured electrophysiologically under depolarized conditions, TROX-1 inhibits recombinant hCa\textsubscript{V}2.2 currents with an estimated IC\textsubscript{50} of 0.11 μM. However, when cells are hyperpolarized to minimize open and inactivated state inhibition, TROX-1 potency is reduced, blocking only 45 ± 7% of the current at 3 μM. These results are in good agreement with IC\textsubscript{50} values for TROX-1 inhibition of native calcium channel currents from dissociated rat DRG neurons under depolarized (0.4 μM) and hyperpolarized (μM) conditions (Abbadie et al., 2010). The state-dependence of TROX-1 inhibition of calcium channels was also observed using a calcium influx assay where the TROX-1 IC\textsubscript{50} shifted from 0.69 μM under high external potassium (14 mM K\textsuperscript{+}, partially inactivated) conditions to 9.48 μM under low external potassium (4 mM K\textsuperscript{+}) conditions. This is in reasonable agreement with the 0.27 μM and >10 μM values from Abbadie et al. (2010) which were obtained using a different cell line and with 30 mM K\textsuperscript{+} for the high potassium condition. Electrophysiologically, TROX-1 also inhibited Ca\textsubscript{V}2.2 channels in a use-dependent manner. TROX-1 inhibited Ca\textsubscript{V}2.2 current during the 20\textsuperscript{th} pulse of a 2 Hz train approximately 10-fold more potently than during the 1\textsuperscript{st} pulse of the train.

Since TROX-1 shows selectivity for Ca\textsubscript{V}2.2 over Ca\textsubscript{V}1.2 (L-type, 18 μM) and Ca\textsubscript{V}3.1/3.2 (T-type, 15 μM and > 20 μM, respectively) (Abbadie et al., 2010) we also wanted to determine TROX-1 selectivity within the Ca\textsubscript{V}2 subfamily. Electrophysiologically, when cells are depolarized to obtain comparable levels of inactivation, TROX-1 has a similar potency across Ca\textsubscript{V}2.1, Ca\textsubscript{V}2.2 and Ca\textsubscript{V}2.3 calcium
channels. However, when cells are voltage-clamped at -100 mV, TROX-1 appears >30-fold selective for CaV2.2 and CaV2.3 relative to CaV2.1. Interestingly, while -100 mV is near the foot of the inactivation curve for both CaV2.2 and CaV2.3, it is ~60 mV hyperpolarized from the foot of the inactivation curve for CaV2.1 (see Fig 1B and Dai et al. (2008) Fig. 2D). The apparent difference in potency, therefore, may reflect the fact that the CaV2.1 potency at -100 mV better approximates closed-state inhibition. The results from the calcium influx experiments support this interpretation. In the calcium influx assays, the relationship between IC50 and external potassium is shifted to higher potassium concentrations (more depolarized) for CaV2.1 relative to CaV2.2 and CaV2.3 (Fig. 7A-C). If, however, IC50 values are plotted versus fractional reduction in calcium signal to normalize for channel inactivation, TROX-1 potency is essentially identical for CaV2.1, CaV2.2 and CaV2.3 across a range of inactivation levels (Fig. 7D). These results suggest that TROX-1 is interacting with the inactivated state of the channel, although these data do not exclude other potential mechanisms such as effects on open channels, channel activation, or closed-closed channel state transitions the might occur at depolarized potentials. While these results indicate that there may be little true molecular selectivity within the CaV2 subfamily, TROX-1 could still be functionally selective against less inactivated CaV2 calcium channels. This is likely a physiologically relevant consideration as CaV2 inactivation levels are not only modulated by the voltage and activity of the neurons expressing them, but also can be dependent on the splice variant (Bourinet et al., 1999; Thaler et al., 2004), co-expressed auxiliary subunit (De Waard and Campbell, 1995), or interacting proteins including synaptic proteins (Bezprozvanny et al., 1995; Kiyonaka et al., 2007; Zhong et al., 1999)
Molecular selectivity can be examined in both the electrophysiological and calcium influx assays by measuring potency under similar levels of inactivation (see also Dai et al., 2008), however, more caution should be taken when comparing the absolute degree of state-dependence across the different CaV2 assays. The degree of state-dependence is determined by comparing the potency under depolarized conditions to the potency under hyperpolarized conditions where channels are presumed to be largely in the closed-state. However, as discussed above for the electrophysiological assay, the potency values in the calcium influx assay under hyperpolarized conditions (low potassium) are likely influenced by the proximity of the cell resting potential to the foot of the inactivation curve. CaV2.1 and CaV2.2 channels appear largely non-inactivated at 4 mM extracellular K⁺ in these cell lines since the top of the inactivation curves are relatively flat (Figs. 7A,B). The decreasing signal for CaV2.3, however, suggests that it is close to the foot of its inactivation curve and this may contribute to its slightly increased potency in 4 mM K⁺ (Fig. 7C) and, therefore, its reduced apparent state-dependence. As a result, the state-dependent measures from these assays are most useful for comparing different compounds on the same channel rather than the same compound across different channels.

There is a tendency for TROX-1 to appear more potent in the electrophysiological assays. This is consistent with that reported for two other CaV2.2 inhibitors assessed in these same assays (Dai et al., 2008) and may be tied to differences between the assay formats. While the cell membrane potentials in the calcium influx assay are likely to be relatively constant during compound incubation, the cells are depolarized periodically in
the electrophysiological assay which could contribute an additional use-dependent component to the inhibition.

The issue of selectivity within the Cav2 subfamily of calcium channels raises the question- how might the individual inhibitory activities on Cav2.1, Cav2.2, and Cav2.3 influence overall efficacy and safety profiles? Genetic ablation of these channels in mice likely only provides a partial answer. Cav2.3−/− mice, for example, have been reported to be resistant to inflammatory pain but otherwise exhibit a predominantly normal phenotype with alterations in glucose metabolism (Matsuda et al., 2001; Saegusa et al., 2000; Wilson et al., 2000). Reports on the role of Cav2.1 channels in pain have been less straightforward with evidence of reduced pain sensitivity in the Cav2.1 knockout mice (Luvisetto et al., 2006) but hypersensitivity using pharmacological blockade of Cav2.1 at supraspinal levels (Ebersberger et al., 2004; Knight et al., 2002). In terms of potential adverse effects, Cav2.1−/− mice, which die within 3-4 weeks of birth, exhibit ataxia, dystonia, and absence seizures. This phenotype is consistent with human Cav2.1 loss-of-function mutations which result in episodic ataxia and absence seizures (Pietrobon, 2005). Despite this, the efficacy and safety data of TROX-1 in animal models suggest that an adequate safety window can be obtained with a state-dependent, non-selective Cav2 inhibitor (Abbadie et al., 2010). The therapeutic window for a given compound is likely to depend on both its molecular selectivity as well as its degree of state-dependence. Until additional studies are reported for a range of Cav2.2 inhibitors, the combination of selectivity and state-dependent profiles that best maximize the safety window will remain an open question.
A number of small molecule Cav2.2 inhibitors have now been reported with various potencies and selectivity profiles (Yamamoto and Takahara, 2009). High affinity Cav1.2 (L-type) calcium channel inhibitors carry known cardiovascular liabilities and much effort has focused on developing Cav2.2 inhibitors with selectivity over L-type channels (Abbadie et al., 2010; Zamponi et al., 2009; Zhang et al., 2008). Selectivity against Cav3 (T-type) calcium channels and other Cav2 subfamily members has also been reported but, in general, have been much more limited (Yamamoto and Takahara, 2009). As shown here, for state-dependent inhibitors, it is important to generate selectivity data in assays producing similar degrees of channel inactivation. Furthermore, a more informative and detailed understanding of inhibitor selectivity profiles can be obtained by looking at potencies across a range of voltages and inactivation levels, particularly for closely related family members where true molecular selectivity may be more difficult to obtain. This is illustrated in the electrophysiological selectivity data for Cav2.1, Cav2.2 and Cav2.3 at -100 mV where TROX-1 appears to be ~30-fold selective over Cav2.1 channels but, actually, shows no true molecular selectivity.

TROX-1 is an orally available, small molecule Cav2.2 inhibitor with efficacy in a number of animal models and a demonstrated therapeutic window in animals over cardiovascular and neurological side effects (Abbadie et al., 2010). This paper provides a detailed characterization of the state-dependent and use-dependent properties of TROX-1. The comprehensive selectivity characterization shows that TROX-1 is a state-dependent inhibitor of all members of the Cav2 subfamily with similar potency when normalized to the degree of inactivation. Together, these data support the idea that a state-dependent Cav2 inhibitor can provide an improved therapeutic window over a relatively state-
independent Ca\textsubscript{v}2.2 inhibitor, such as ziconotide (Abbadie et al., 2010; Snutch, 2005). Additionally, this paper presents the most comprehensive characterization of a small molecule Cav2 inhibitor to date and should further promote the use of TROX-1 as a benchmark compound. As detailed compound characterizations become available for additional Ca\textsubscript{v}2 inhibitors, our understanding of how state-dependence and selectivity influences safety margins and analgesic efficacy will improve. The preclinical profile of TROX-1 suggests a potential future avenue to develop small molecule Ca\textsubscript{v}2.2 blockers for clinical trials. Ultimately, optimizing state-dependence and selectivity will be essential to realize the full therapeutic potential of targeting Ca\textsubscript{v}2.2 channels.
Acknowledgements: We thank members of the Ion Channel Department, Merck Research Labs and Dr. Elizabeth Tringham, Zalicus Pharmaceuticals, for helpful discussions.

Authorship Contributions:
Participated in Research Design: AMS, JH, RMB, MMS, SPA, CE, TPS, JLD, GJK and OBM

Conducted Experiments: AMS, JH, RMB, GD, RJH, KSR, MMS, VAW, CE

Contributed new reagents or analytic tools: DP, SBH, CL, JLD

Performed Data analysis: AMS, JH, RMB, GD, RJH, KSR, MMS, VAW, CE, OBM

Wrote or contributed to the writing of the manuscript: AMS, JH, CE, OBM
References


Luvisetto S, Marinelli S, Panasiti MS, D'Amato FR, Fletcher CF, Pavone F and Pietrobon D (2006) Pain sensitivity in mice lacking the Ca(v)2.1alpha1 subunit of P/Q-type Ca2+ channels. *Neuroscience* 142(3):823-832.


Footnotes  Present addresses of authors:

A.M.S.
Abbott Neuroscience
100 Abbott Park Rd.
Abbott Park, IL 60064

J.H.
Biochemical Pharmacology | Small Molecule Drug Discovery
Genentech Research & Early Development
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080

R.J.H.
Nanion Technologies Inc.
675 US Highway One
North Brunswick, NJ 08902

K.S.R.
Pain/Migraine DHT
Eli Lilly and Company
Indianapolis, Indiana 46285

V.A.W.
Koltan Pharmaceuticals
300 George St, Suite 530
New Haven, CT 06511

S.P.A.
Pain/Migraine DHT
Eli Lilly and Company
Indianapolis, Indiana 46285

G.J.K.
Kanalis Consulting
5 Ashbrook Drive
Edison, New Jersey 08820

O.B.M.
Johns Hopkins Ion Channel Center
High Throughput Biology Center
Department of Neuroscience
Johns Hopkins Medical School
733 North Broadway
Baltimore, MD 21205
Financial Disclosure Information

A.M.S., J.H., R.M.B., G.D., R.J.H., K.S.R., M.M.S., V.A.W., S.B.H., C.L., J.L.D., G.J.K. and O.B.M. are present or former employees of Merck Research Laboratories and may hold stock or stock options in Merck & Co. S.P.A., C.E., D.P. and T.P.S. are present or former employees in Zalicus Pharmaceuticals and may hold stock or stock options in Zalicus Pharmaceuticals.

Andrew M. Swensen, James Herrington - Contributed equally to this work
Figure Legends

Figure 1. Characterization of bMHN-4 Ca\textsubscript{v}2.2 cell line. (A) The bMHN-4 Ca\textsubscript{v}2.2 cell line (n=14 cells) showed improved current stability relative to the 2H8 cell line (n=7 cells). Peak current amplitudes were measured on PatchXpress every 15 seconds in response to a 50 ms depolarizing step to +10 mV from a holding potential of –90 mV. (B) Characterization of the voltage-dependence of bMHN-4 currents. The current vs voltage relationship shows that the peak current amplitudes were elicited near +5 mV (n=5 cells). Activation (n=4 cells) and inactivation (n=5 cells) data were fit with a Boltzmann relationship (see Materials and Methods for protocol details). Best fits to the data yielded a half activation voltage of +4 mV with a slope factor of 9.1 and a half inactivation voltage of -80 mV with a slope factor of -11.5. Data are shown as mean ± S.E.M.. (C) Example illustrating the inhibition of current from the bMHN-4 cell line by 500 nM of the Ca\textsubscript{v}2.2-selective peptidyl inhibitor, ω-conotoxin GVIA. Current was elicited in response to a 20 ms step to +10 mV from a holding potential of -110 mV.

Figure 2. TROX-1 inhibition of Ca\textsubscript{v}2.2 current assessed by manual electrophysiology. (A) Chemical structure of the substituted N-triazole oxindole, TROX-1. (B, C) Representative current traces illustrating the inhibition of Ca\textsubscript{v}2.2 current by 300 nM TROX-1 utilizing the depolarized (B) and hyperpolarized (C) electrophysiological protocols. (D) Concentration-response data for TROX-1 under depolarized (n=3 cells) and hyperpolarized (n=3-4 cells) conditions. Voltage protocol details are given in the text. Solid line is a fit of the Hill equation to the data; IC\textsubscript{50} value from the fit is given in the text.
Figure 3. State-dependence of TROX-1 inhibition of Ca\textsubscript{v}2.2 channels measured by automated electrophysiology. (A) Plot of the peak inward current versus time for a cell (bMHN-4) recorded on the PatchXpress\textsuperscript{TM} (left). The solid bars represent when TROX-1 was present in the well at the concentrations shown. The membrane potential was stepped to +10 mV every 15 seconds from a holding potential of -70 mV. Representative leakage-subtracted currents prior to and after adding 0.3 uM and 3 uM TROX-1 are shown at right. (B) Plot of peak inward current versus time (left) for a different cell under identical conditions as in A except that the holding potential was -110 mV. Representative leakage-subtracted currents prior to and after adding 3 uM and 10 uM TROX-1 are shown at right. The peak tail current has been truncated for scaling purposes. (C) Plot of the average percent inhibition of peak inward Ca\textsubscript{v}2.2 current versus the concentration of TROX-1. The solid lines are fits of the Hill equation to the data; IC\textsubscript{50} values from the fits are given in the text. For -70 mV and -90 mV, n=6 for each data point. For -110 mV data, n=6 for 1 uM and 30 uM and n=8 for 3 uM and 10 uM.

Figure 4. Use-dependent inhibition of Ca\textsubscript{v}2.2 channels by TROX-1. (A) Representative Ca\textsubscript{v}2.2 currents recorded on the PatchXpress prior to and after application of 3 uM TROX-1. CBK cells were voltage clamped at -60 mV and trains of twenty 25 msec pulses to +20 mV were applied at a frequency of 2 Hz every 5 minutes. Shown are the currents in response to Pulse 1 (top) and Pulse 20 (bottom) of the train. (B) Plot of the average percent inhibition of peak inward Ca\textsubscript{v}2.2 current at Pulse 1 and Pulse 20 versus the concentration of TROX-1. Solid lines are fits of the Hill equation to the data.
values from the fits are given in the text. For each data point n=5. (C) Plots of peak current (left) and end current amplitude (right) versus sweep number prior to (open symbols) and following application of 3 μM TROX-1 (closed symbols) for the recording shown in (A).

**Figure 5.** Comparison of TROX-1 inhibition of Ca\(_{\text{V}2.1}\), Ca\(_{\text{V}2.2}\), and Ca\(_{\text{V}2.3}\) current assessed by manual electrophysiology. Utilizing the depolarized voltage format where Ca\(_{\text{V}2.1}\), Ca\(_{\text{V}2.2}\) and Ca\(_{\text{V}2.3}\) channels were similarly inactivated, TROX-1 inhibited all three Ca\(_{\text{V}2}\) subfamily members with a similar potency. Although TROX-1 displayed state-dependent inhibition of all three Ca\(_{\text{V}2}\) subfamily members, TROX-1 inhibition measured utilizing the hyperpolarized voltage format was less potent for Ca\(_{\text{V}2.1}\) than that observed for Ca\(_{\text{V}2.2}\) and Ca\(_{\text{V}2.3}\). Voltage protocol details are given in the text. Solid lines are fits of the Hill equation to the data; IC\(_{50}\) values from the fits are given in the text. For the depolarized voltage format, n=6, 9 and 7 cells for Ca\(_{\text{V}2.1}\), Ca\(_{\text{V}2.2}\) and Ca\(_{\text{V}2.3}\), respectively. For the hyperpolarized voltage format, n=5, 5 and 9 cells for Ca\(_{\text{V}2.1}\), Ca\(_{\text{V}2.2}\), and Ca\(_{\text{V}2.3}\), respectively.

**Figure 6.** Selectivity and state-dependent inhibition of Ca\(_{\text{V}2.1}\), Ca\(_{\text{V}2.2}\) and Ca\(_{\text{V}2.3}\) channels in a calcium-influx assay. Top Panels: Data from a row of twenty four wells in a 384 well assay plate showing calcium influx under either hyperpolarized (A, 4 mM K\(^+\) pre-incubation) or depolarized (B, 14 mM K\(^+\) pre-incubation) conditions followed by a 140 mM K\(^+\) addition (1:1) to depolarize cells and open channels. The leftmost two wells in each row contained 10 μM of a nonselective Cav2.x blocker, the next two wells from
the left contain control buffer, and the following wells contain increasing concentrations of TROX-1 in a ten point titration format in duplicate from 1 nM to 30 µM. Bottom Panels: Analysis of TROX-1 concentration-response data for each experiment under hyperpolarized (A) or depolarized (B) conditions. Data are reported as the mean ± S.E.M (n=4). Solid lines are fits of the Hill equation to the data; IC$_{50}$ values from the fits are given in the text.

**Figure 7.** Relationship between TROX-1 potency and calcium channel inactivation for Ca$_{V}2.1$, Ca$_{V}2.2$ and Ca$_{V}2.3$ channels in a calcium-influx assay. (A, B and C) Plots of TROX-1 IC$_{50}$ values (colored symbols; n=4 experiments) and peak fluorescent signal (black squares; one experiment in quadruplicate) vs the pre-incubation external potassium concentration for Ca$_{V}2.1$ (A), Ca$_{V}2.2$ (B) and Ca$_{V}2.3$ (C). (D) Plot of TROX-1 IC$_{50}$ values vs the fractional reduction in the peak calcium signal for Ca$_{V}2.1$ (blue), Ca$_{V}2.2$ (red) and Ca$_{V}2.3$ (green).
Tables

**TABLE 1.** Comparison of current expression in the CBK, 2H8, and bMHN-4 Cav2.2 stable cell lines as measured by automated electrophysiology. Peak current amplitudes were measured on PatchXpress in response to a 50 ms depolarizing step to +10 mV from a holding potential of –90 mV. Data are reported as mean ± S.E.M.

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Current at +10 mV</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBK</td>
<td>1.6 ± 0.6 nA</td>
<td>8</td>
</tr>
<tr>
<td>2H8</td>
<td>5.6 ± 0.7 nA</td>
<td>21</td>
</tr>
<tr>
<td>bMHN-4</td>
<td>2.2 ± 0.5 nA</td>
<td>14</td>
</tr>
</tbody>
</table>
Figure 1

A

![Graph showing relative current over time](image)

B

- **current vs voltage**
  - normalized current vs voltage (mV)
  - normalized current vs prepulse voltage (mV)
  - normalized current vs prepulse voltage (mV)

C

- **ω-Conotoxin GVIA**
  - Control

[Graphs and data points showing current changes](image)
Figure 5

Graphs showing percent inhibition against [TROX-1] (μM) for Ca\(_{\text{v}}\)2.1, Ca\(_{\text{v}}\)2.2, and Ca\(_{\text{v}}\)2.3.
Figure 6

A 4 mM K⁺

B 14 mM K⁺